Mark Vander Lugt

693 total citations
14 papers, 380 citations indexed

About

Mark Vander Lugt is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Mark Vander Lugt has authored 14 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 5 papers in Immunology and 4 papers in Oncology. Recurrent topics in Mark Vander Lugt's work include Hematopoietic Stem Cell Transplantation (8 papers), Acute Myeloid Leukemia Research (3 papers) and T-cell and B-cell Immunology (3 papers). Mark Vander Lugt is often cited by papers focused on Hematopoietic Stem Cell Transplantation (8 papers), Acute Myeloid Leukemia Research (3 papers) and T-cell and B-cell Immunology (3 papers). Mark Vander Lugt collaborates with scholars based in United States, Japan and Germany. Mark Vander Lugt's co-authors include Pavan Reddy, James L.M. Ferrara, Sophie Paczesny, Thomas Braun, Andrew C. Harris, John E. Levine, Sung Won Choi, Karin Landfried, Takanori Teshima and Koichi Akashi and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Mark Vander Lugt

13 papers receiving 378 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Vander Lugt United States 6 294 171 60 51 40 14 380
Benjamin Watkins United States 10 137 0.5× 139 0.8× 54 0.9× 31 0.6× 42 1.1× 32 319
Søren Lykke Petersen Denmark 9 180 0.6× 146 0.9× 65 1.1× 37 0.7× 39 1.0× 33 305
Johan Törlén Sweden 10 224 0.8× 115 0.7× 76 1.3× 26 0.5× 43 1.1× 16 307
Kazuya Ishiwata Japan 10 269 0.9× 100 0.6× 105 1.8× 36 0.7× 67 1.7× 54 373
Emeline Masson France 8 136 0.5× 199 1.2× 40 0.7× 35 0.7× 18 0.5× 11 349
Rebecca Hawke United States 5 313 1.1× 107 0.6× 93 1.6× 27 0.5× 121 3.0× 9 356
Ioannis Politikos United States 8 173 0.6× 61 0.4× 101 1.7× 30 0.6× 56 1.4× 30 278
Sandeep Nagra United Kingdom 13 351 1.2× 134 0.8× 143 2.4× 61 1.2× 59 1.5× 21 518
M. Schaffer Sweden 6 238 0.8× 159 0.9× 63 1.1× 21 0.4× 63 1.6× 8 335
Geothy Chakupurakal Germany 12 156 0.5× 157 0.9× 126 2.1× 31 0.6× 60 1.5× 28 369

Countries citing papers authored by Mark Vander Lugt

Since Specialization
Citations

This map shows the geographic impact of Mark Vander Lugt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Vander Lugt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Vander Lugt more than expected).

Fields of papers citing papers by Mark Vander Lugt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Vander Lugt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Vander Lugt. The network helps show where Mark Vander Lugt may publish in the future.

Co-authorship network of co-authors of Mark Vander Lugt

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Vander Lugt. A scholar is included among the top collaborators of Mark Vander Lugt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Vander Lugt. Mark Vander Lugt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Escolar, Maria L., Mark Vander Lugt, Raymond Wang, et al.. (2024). O30: REKLAIM: A first in human phase Ib clinical trial of FBX-101 (AAVrh10.GALC) intravenously administered after UCBT for infantile Krabbe disease. SHILAP Revista de lepidopterología. 2. 100875–100875. 1 indexed citations
2.
3.
Escolar, Maria L., et al.. (2023). P014: First-in-human phase 1/2 trial of intravenous FBX-101 with cord blood transplantation increases GALC, brain and motor development in infantile Krabbe. SHILAP Revista de lepidopterología. 1(1). 100024–100024. 1 indexed citations
4.
Marsh, Rebecca, Kyle Hebert, Soyoung Kim, et al.. (2021). Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. Journal of Allergy and Clinical Immunology. 149(3). 1097–1104.e2. 21 indexed citations
5.
6.
Braun, Thomas, John Magenau, Sung Won Choi, et al.. (2019). The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD). Biology of Blood and Marrow Transplantation. 25(3). S26–S27. 5 indexed citations
7.
Ozolek, John A., et al.. (2017). Disseminated Lichtheimia ramosa Infection After Hematopoietic Stem Cell Transplantation in a Child With Chronic Granulomatous Disease. The Pediatric Infectious Disease Journal. 36(12). 1222–1224. 6 indexed citations
8.
Lugt, Mark Vander, Xiaohua Chen, Hey Chong, et al.. (2016). Excellent Outcomes Using Reduced-Intensity Conditioning for Patients with Inborn Errors of Immunity, Hematopoiesis, and Metabolism. Biology of Blood and Marrow Transplantation. 22(3). S100–S101. 1 indexed citations
9.
Chen, Xiaohua, Mark Vander Lugt, & Paul Szabolcs. (2014). Deficiency of Foxp3/Helios co-expressing regulatory T-cells correlates with clinical acitvity in autoimmunity (HUM7P.316). The Journal of Immunology. 192(Supplement_1). 184.25–184.25. 4 indexed citations
10.
Harris, Andrew C., James L.M. Ferrara, Thomas Braun, et al.. (2012). Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 119(12). 2960–2963. 104 indexed citations
11.
Lugt, Mark Vander, et al.. (2011). An unusual case of membranous nephropathy associated with an ovarian tumor. Pediatric Nephrology. 26(12). 2249–2251. 3 indexed citations
12.
Paczesny, Sophie, Thomas Braun, Mark Vander Lugt, et al.. (2011). A Three Biomarker Panel at Days 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation. 17(2). S167–S167. 5 indexed citations
13.
Ferrara, James L.M., Andrew C. Harris, Joel K. Greenson, et al.. (2011). Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 118(25). 6702–6708. 218 indexed citations
14.
Paczesny, Sophie, Thomas Braun, Mark Vander Lugt, et al.. (2010). Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease. Blood. 116(21). 675–675. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Benjamin Watkins Breakdown of academic impact, for papers by Søren Lykke Petersen Breakdown of academic impact, for papers by Johan Törlén Breakdown of academic impact, for papers by Kazuya Ishiwata Breakdown of academic impact, for papers by Emeline Masson Breakdown of academic impact, for papers by Rebecca Hawke Breakdown of academic impact, for papers by Ioannis Politikos Breakdown of academic impact, for papers by Sandeep Nagra Breakdown of academic impact, for papers by M. Schaffer Breakdown of academic impact, for papers by Geothy Chakupurakal
Rankless by CCL
2026